2 min read
As of January 1, 2026, the Jordanian pharmaceutical sector has entered a new phase. After years of preparation and upgrades, the Jordan Food and Drug Administration (JFDA) officially became the 57th member of the Pharmaceutical Inspection Co-operation Scheme (PIC/S).
For professionals working in Regulatory affairs (RA) and quality assurance (QA) across Jordan, this is more than just an achievement—it is a major shift. Understanding the JFDA PIC/S membership impact is now essential to stay compliant and take advantage of new global opportunities.
A Global Boost for “Made in Jordan”:
One of the most immediate outcomes of the JFDA PIC/S membership impact is the stronger global recognition of Jordanian pharmaceutical products. By joining PIC/S, Jordan’s Good Manufacturing Practice (GMP) standards are now aligned with some of the world’s most trusted Regulatory authorities, reinforcing JFDA GMP standards PIC/S alignment.
For local manufacturers, this acts like a “global passport.” In the past, exporting to regulated markets often required multiple audits by different authorities. This created delays and increased costs.
With PIC/S, member countries can share inspection reports and rely on each other’s findings. This reduces repeated audits and supports Jordan pharmaceutical export opportunities PIC/S, helping companies enter international markets faster and more efficiently.
JFDA PIC/S Membership Impact on GMP Compliance Standards:
PIC/S membership also brings important changes to how companies manage compliance at the operational level. JFDA inspections are increasingly aligned with PIC/S GMP guidelines, reflecting evolving PIC/S compliance requirements Jordan and setting higher expectations for manufacturers.
In 2026, key focus areas include:
Sterile Manufacturing (Annex 1):
Companies must now implement strong contamination control strategies (CCS). This means moving from basic testing to a more proactive, risk-based approach to prevent contamination.
Data Integrity (ALCOA+ principles):
Ensuring accurate and reliable data is critical. Manual records are gradually being replaced by validated digital systems that ensure data is complete, traceable, and secure.
Quality Risk Management (QRM):
Inspections are no longer checklist-based. Regulators expect companies to apply risk management principles in all areas, including deviations, change control, and CAPA (Corrective and Preventive Actions).
These changes highlight how compliance expectations are evolving and pushing companies toward stronger, more robust quality systems, reflecting the broader impact of PIC/S on pharmaceutical manufacturers.
Stronger Supply Chain and Investment Opportunities:
The impact of PIC/S membership goes beyond manufacturing. Jordan is now part of the global rapid alert system, which helps authorities quickly share information about defective or unsafe medicines.
This improves the safety and reliability of the pharmaceutical supply chain in Jordan and the wider region.
At the same time, PIC/S membership increases Jordan’s attractiveness as a manufacturing hub. International pharmaceutical companies are more likely to partner with Jordanian firms, especially for contract manufacturing, because of the globally recognized Regulatory standards.
Preparing for the Future:
To keep up with these changes, companies must focus on continuous improvement and training. Traditional approaches to Regulatory and quality systems are no longer enough.
Organizations need to build a culture of “inspection readiness,” where processes, documentation, and systems are always prepared for review. Investing in technology, skilled teams, and strong quality systems will be key to long-term success.
Conclusion
JFDA’s PIC/S membership marks a major turning point for the Jordanian pharmaceutical industry. While it brings higher expectations and the need for investment, it also opens the door to global markets, stronger partnerships, and improved patient safety.
Jordan is no longer just a regional player—it is now part of a globally recognized Regulatory network. Companies that understand the JFDA PIC/S membership impact and adapt quickly will be well-positioned to grow and compete internationally.
The PIC/S era is here, offering a clear path for Jordanian pharma to move forward with confidence and credibility. Connect with our experts to navigate this transition effectively.
